Clinical Trial Update: PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Pembrolizumab immunotherapy to standard chemotherapy in advanced malignant pleural mesothelioma has completed with results posted in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Pleural Mesothelioma Malignant Advanced | Phase 3 | Status: COMPLETED | Results posted: 2022-02-07